Mankind Pharma IPO: The Mankind Pharma Ltd initial public offering (IPO) opened for subscription on April 25, 2023 and will remain open for bids until April 27, 2023. This means that today is the last day to request the value of the public issue €4,326.36 million. According to Mankind Pharma’s IPO subscription status, the public offering was subscribed 0.88 times after two bidding days. According to market observers, Mankind Pharma stock is available at a premium of €70 today in the gray market.
Mankind Pharma IPO: The Mankind Pharma Ltd initial public offering (IPO) opened for subscription on April 25, 2023 and will remain open for bids until April 27, 2023. This means that today is the last day to request the value of the public issue €4,326.36 million. According to Mankind Pharma’s IPO subscription status, the public offering was subscribed 0.88 times after two bidding days. According to market observers, Mankind Pharma stock is available at a premium of €70 today in the gray market.
1]Mankind Pharma IPO GMP: According to market observers, Mankind Pharma IPO is GMP (grey market premium) today €70 that is €20 lower from the GMP of its Wednesday from €90 per share.
1]Mankind Pharma IPO GMP: According to market observers, Mankind Pharma IPO is GMP (grey market premium) today €70 that is €20 lower from the GMP of its Wednesday from €90 per share.
2]Mankind Pharma IPO subscription Status: After two days of bidding, the public issue was subscribed 0.88 times, while the retail portion was subscribed 0.25 times. The public offering was fully subscribed in the NII and QIB categories. In the NII category, the IPO was subscribed for 1.02 times, while in the QIB segment it was subscribed for 1.86 times of its original offering.
2]Mankind Pharma IPO subscription Status: After two days of bidding, the public issue was subscribed 0.88 times, while the retail portion was subscribed 0.25 times. The public offering was fully subscribed in the NII and QIB categories. In the NII category, the IPO was subscribed for 1.02 times, while in the QIB segment it was subscribed for 1.86 times of its original offering.
3]Mankind Pharma IPO Date: The public issue opened for subscription on April 25, 2023 and will remain open for bids until April 27, 2023.
3]Mankind Pharma IPO Date: The public issue opened for subscription on April 25, 2023 and will remain open for bids until April 27, 2023.
4]Mankind Pharma IPO price range: Manforce and Prega News Maker Company has set the price range of their public offering to €1026 bis €1080 pieces.
4]Mankind Pharma IPO price range: Manforce and Prega News Maker Company has set the price range of their public offering to €1026 bis €1080 pieces.
5]Mankind Pharma IPO lot size: A bidder can apply in lots, and one lot of the IPO is 13 shares.
5]Mankind Pharma IPO lot size: A bidder can apply in lots, and one lot of the IPO is 13 shares.
6]Mankind Pharma IPO Investment Limit: Since one lot will have 13 company shares, the minimum amount required for a retail investor to file for Mankind Pharma’s IPO is €14,040 ( €1080×13).
6]Mankind Pharma IPO Investment Limit: Since one lot will have 13 company shares, the minimum amount required for a retail investor to file for Mankind Pharma’s IPO is €14,040 ( €1080×13).
7]Mankind Pharma IPO Grant Date: The most likely date for the stock grant is May 3, 2023.
7]Mankind Pharma IPO Grant Date: The most likely date for the stock grant is May 3, 2023.
8]Mankind Pharma IPO Registrar: KFin Technologies Limited has been appointed as the Official Registrar of the IPO.
8]Mankind Pharma IPO Registrar: KFin Technologies Limited has been appointed as the Official Registrar of the IPO.
9]Mankind Pharma IPO listing Date: The public offering has been proposed for listing on both the BSE and NSE and the expected listing date for the shares is 8 May 2023.
9]Mankind Pharma IPO listing Date: The public offering has been proposed for listing on both the BSE and NSE and the expected listing date for the shares is 8 May 2023.
10]Review of Mankind Pharma IPO: Canara Bank Securities assigned a ‘subscribe’ tag to Mankind Pharma’s IPO, saying, “The Company has consistently outperformed IPM in value growth and has the third highest compound annual contribution from volume growth. The Company is gradually increasing its R&D spending. The Company also has a strong market share of consumer healthcare segment brands and intends to further grow the segment. It also plans to expand into new chronic therapeutic areas. The company reported its revenues at a CAGR of 15% for the FY20- 22 with EBITDA margin increased in the range of 25-27% The 9MFY23 was impacted by high API prices, one off due to the acquisition and increase in hiring of MRs The company is net debt free with working capital of 45-50 days The company appears fairly valued in comparison given its decent yield ratios versus its peers. We recommend SUBSCRIBE long-term.”
10]Review of Mankind Pharma IPO: Canara Bank Securities assigned a ‘subscribe’ tag to Mankind Pharma’s IPO, saying, “The Company has consistently outperformed IPM in value growth and has the third highest compound annual contribution from volume growth. The Company is gradually increasing its R&D spending. The Company also has a strong market share of consumer healthcare segment brands and intends to further grow the segment. It also plans to expand into new chronic therapeutic areas. The company reported its revenues at a CAGR of 15% for the FY20- 22 with EBITDA margin increased in the range of 25-27% The 9MFY23 was impacted by high API prices, one off due to the acquisition and increase in hiring of MRs The company is net debt free with working capital of 45-50 days The company appears fairly valued in comparison given the decent yield ratios versus its peers. We recommend SUBSCRIBE long-term.”
Choice Broking gives Mankind Pharma’s IPO a Buy label, saying, “Mankind is India’s fourth-largest pharmaceutical company by domestic sales and third-largest by sales volume for the 12-month period (TTM) to December 2022. It is a domestically focused pharmaceutical formulation company with a 4.3% value market share and 5.6% volume share in IPM. In addition to developing, manufacturing and marketing pharmaceutical formulations, the Company also manufactures and develops several consumer healthcare products.”
Choice Broking gives Mankind Pharma’s IPO a Buy label, saying, “Mankind is India’s fourth-largest pharmaceutical company by domestic sales and third-largest by sales volume for the 12-month period (TTM) to December 2022. It is a domestically focused pharmaceutical formulation company with a 4.3% value market share and 5.6% volume share in IPM. In addition to developing, manufacturing and marketing pharmaceutical formulations, the Company also manufactures and develops several consumer healthcare products.”
Disclaimer: The views and recommendations made above are those of individual analysts or brokerage firms and not Mint. We advise investors to consult certified professionals before making any investment decisions.
Disclaimer: The views and recommendations made above are those of individual analysts or brokerage firms and not Mint. We advise investors to consult certified professionals before making any investment decisions.
subjects
Comments are closed.